*********************************
There is now a CONTENT FREEZE for Mercury while we switch to a new platform. It began on Friday, March 10 at 6pm and will end on Wednesday, March 15 at noon. No new content can be created during this time, but all material in the system as of the beginning of the freeze will be migrated to the new platform, including users and groups. Functionally the new site is identical to the old one. webteam@gatech.edu
*********************************
Please contact James Dahlman with questions.
Summary Sentence: Oxana Beskrovnaya - Chief Scientific Officer, Dyne Therapeutics
Full Summary: Oxana Beskrovnaya - Chief Scientific Officer, Dyne Therapeutics
Gene Editing / Therapy Seminar Series 2021Oxana Beskrovnaya
Chief Scientific Officer
Dyne Therapeutics
Join this virtual event via BlueJeans
BIOGRAPHY
Oxana is an accomplished R&D leader with a strong track record of discovering and developing first-in-class therapeutics for rare genetic diseases. She has served as Dyne’s chief scientific officer since June 2021 after joining Dyne as senior vice president, head of research in January 2020. Prior to joining Dyne, Oxana served as head of musculoskeletal and renal research in Sanofi’s rare disease and neurological unit, advancing a pipeline of drug candidates using multiple therapeutic modalities, including nucleic acids, proteins and small molecules. She is the author of numerous patents, invited reviews, editorials, book chapters and original research articles in major scientific journals. Oxana received her Ph.D. in genetics from Moscow Genetics Institute, followed by postdoctoral fellowship training in neuromuscular diseases at the Howard Hughes Medical Institute at the University of Iowa.
The Gene Editing / Gene Therapy Seminar Series features leading academic, translational, and investor speakers in e-talks through the summer and fall.
